Showing 8981-8990 of 21419 results for "".
Clinical Care Implications of ALLHAT
https://reachmd.com/programs/diabetes-discourse/clinical-care-implications-of-allhat/5112/The ALLHAT hypertension study results indicated that less costly, traditional diuretics are more effective than newer medicines at lowering high blood pressure and preventing some forms of heart disease. Join host Dr. Steven Edelman and his guest, endocrinologist and director of the endocrinology, dImproving Care for Children with IBD
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/improving-care-children-ibd/9923/Lu Ann Cahn talks with Dr. Jose Fernando about the importance of improving care for children with inflammatory bowel disease (IBD)Optimizing Treatment Intensity in Early-Stage TNBC
https://reachmd.com/programs/project-oncology/early-stage-tnbc-treatment-intensity/50997/New and evolving evidence is reshaping treatment strategies for patients with early-stage triple-negative breast cancer (TNBC), with growing focus on tailoring therapy intensity based on tumor biology and recurrence risk. To learn how this emerging research may be incorporated into clinical practicectDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
https://reachmd.com/programs/project-oncology/ctdna-adjuvant-atezolizumab-mibc-imvigor011/36311/What if molecular relapse in muscle-invasive bladder cancer (MIBC) could be detected early enough to better inform treatment decisions? To find out, Dr. Charles Turck speaks with Dr. Guru Sonpavde to explore new IMvigor011 findings presented at the 2026 ASCO Genitourinary Cancers Symposium. Their diVedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
https://reachmd.com/programs/Audioabstracts/vedolizumab-induction-and-maintenance-therapy-crohns-disease-patients-naive-or-who-have-failed-tumor/9537/Vedolizumab had increased efficacy over placebo in CD patients irrespective of TNF-α antagonist treatment history.It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
https://reachmd.com/programs/cme/it-takes-a-village-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37714/Review a case of geographic atrophy highlighting care coordination gaps and quality improvement opportunities in patients who relocate seasonally for retina care.Novel Strategies for Managing EGFR-mutated mNSCLC: Expert Insights into the Latest Data and Recommendations
https://reachmd.com/programs/cme/managing-egfr-mutated-mnsclc-data-recommendations/56306/Over the past two decades, advances in disease biology and precision medicine have transformed the diagnosis and treatment of non–small cell lung cancer (NSCLC). Improved understanding of NSCLC molecular drivers has led to the development of targeted therapies and immunotherapies that have enhancedConquer the Clutter: Strategies to Identify, Manage, & Overcome Hoarding
https://reachmd.com/programs/book-club/conquer-the-clutter-strategies-to-identify-manage-overcome-hoarding/11245/As many as 21 million Americans may be living with hoarding disorder. How can we help them reclaim their lives from the clutter that’s taken over?Exploring the Role of IgG Autoantibodies in Idiopathic Inflammatory Myopathies (IIM)
https://reachmd.com/programs/medical-industry-feature/igg-autoantibodies-inflammatory-myopathies/32256/Myositis a group of rare autoimmune diseases primarily defined by inflammation of skeletal muscle.1 The potential contributors for myositis isn't fully defined, but the current understanding points to a multifactorial process that includes genetic susceptibility, environmental exposures, and immuneUnderstanding Aging Helps Predict Impact of Ingredients
https://reachmd.com/programs/modern-aesthetics/understanding-aging-helps-predict-impact-of-ingredients/54346/